Publications:

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation.

Frontiers In Oncology

Dong, Wei W; Wang, Congjie C; Wang, Chunsheng C; Zhao, Kewei K; Ma, Zhao Z; Hu, Shanliang S

Publication Date: 2022

Variant appearance in text: EGFR: Thr790Leu

PubMed Link: 36425553

Variant Present in the following documents:

• DataSheet_1.pdf

View BVdb publication page

EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma.

Jto Clinical And Research Reports

Xiang, Chan C; Zhang, Wei W; Xiong, Li-Wen LW; Cai, Xu-Wei XW; Teng, Hao-Hua HH; Zhao, Rui-Ying RY; Shang, Zhan-Xian ZX; Han-Zhang, Han H; Zhang, Lu L; Yan, Li L; Chen, Zhi-Qiu ZQ; Han, Yu-Chen YC

Publication Date: 2021-07

Variant appearance in text: EGFR: Thr790Leu

PubMed Link: 34590035

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page